Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis : Post-Hoc Analysis of the SUPREME Study
© 2023 Talamonti et al..
Purpose: Secukinumab is a fully human monoclonal antibody that inhibits interleukin (IL)-17A approved for the treatment of moderate to severe plaque psoriasis in adults and children. We compared the efficacy and safety of secukinumab in patients aged < 65 years (adult patients) versus patients aged ≥ 65 years (elderly patients) in a post-hoc analysis of the SUPREME study.
Patients and Methods: Patients with moderate to severe plaque psoriasis received subcutaneous secukinumab 300 mg per week for the first 5 weeks, then 300 mg per month. We compared the following outcomes in patients aged ≥ 65 years vs < 65 years: baseline characteristics; PASI50/75/90/100 response rates (improvements ≥ 50%/75%/90%/100% in Psoriasis Area and Severity Index (PASI) from baseline); changes in Dermatology Life Quality Index (DLQI); Hospital Anxiety and Depression Scale (HAD-A, HAD-D) score changes; treatment-emergent adverse events (TEAEs).
Results: Secukinumab was slightly less effective in elderly patients than in adult patients (response rates at week 16: PASI90, 69.4% vs 80.9%, p = 0.4528; PASI100, 44.4% vs 56.7%, p = 0.8973). Elderly and adult patients showed a similar time course of changes in absolute PASI scores. Patients aged ≥ 65 years had a statistically significantly lower improvement in quality of life (mean DLQI reduction) than patients aged < 65 years at week 16 [-5.4 (±4.3) vs -8.8 (±6.9), p = 0.0065] and at week 24 [-5.3 (±4.4) vs -9.2 (±7.1), p = 0.0038]. Secukinumab treatment resulted in comparable mean reductions in anxiety and depression scores in both cohorts at 24 weeks [HAD-A, -1.3 (±3.3) vs -2.1 (±3.8), p = 0.9004; HAD-D, -1.0 (±3.3) vs -1.5 (±3.1), p = 0.4598]. The frequency of TEAEs in the two cohorts was similar (16.7% vs 14.6%, p = 0.7391).
Conclusion: Secukinumab is a valid option for the management of moderate to severe psoriasis in elderly patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Clinical, cosmetic and investigational dermatology - 16(2023) vom: 04., Seite 847-852 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Talamonti, Marina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biologics |
|---|
| Anmerkungen: |
Date Revised 11.04.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.2147/CCID.S400520 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355384108 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355384108 | ||
| 003 | DE-627 | ||
| 005 | 20231226064230.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2147/CCID.S400520 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1184.xml |
| 035 | |a (DE-627)NLM355384108 | ||
| 035 | |a (NLM)37033782 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Talamonti, Marina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis |b Post-Hoc Analysis of the SUPREME Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.04.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 Talamonti et al. | ||
| 520 | |a Purpose: Secukinumab is a fully human monoclonal antibody that inhibits interleukin (IL)-17A approved for the treatment of moderate to severe plaque psoriasis in adults and children. We compared the efficacy and safety of secukinumab in patients aged < 65 years (adult patients) versus patients aged ≥ 65 years (elderly patients) in a post-hoc analysis of the SUPREME study | ||
| 520 | |a Patients and Methods: Patients with moderate to severe plaque psoriasis received subcutaneous secukinumab 300 mg per week for the first 5 weeks, then 300 mg per month. We compared the following outcomes in patients aged ≥ 65 years vs < 65 years: baseline characteristics; PASI50/75/90/100 response rates (improvements ≥ 50%/75%/90%/100% in Psoriasis Area and Severity Index (PASI) from baseline); changes in Dermatology Life Quality Index (DLQI); Hospital Anxiety and Depression Scale (HAD-A, HAD-D) score changes; treatment-emergent adverse events (TEAEs) | ||
| 520 | |a Results: Secukinumab was slightly less effective in elderly patients than in adult patients (response rates at week 16: PASI90, 69.4% vs 80.9%, p = 0.4528; PASI100, 44.4% vs 56.7%, p = 0.8973). Elderly and adult patients showed a similar time course of changes in absolute PASI scores. Patients aged ≥ 65 years had a statistically significantly lower improvement in quality of life (mean DLQI reduction) than patients aged < 65 years at week 16 [-5.4 (±4.3) vs -8.8 (±6.9), p = 0.0065] and at week 24 [-5.3 (±4.4) vs -9.2 (±7.1), p = 0.0038]. Secukinumab treatment resulted in comparable mean reductions in anxiety and depression scores in both cohorts at 24 weeks [HAD-A, -1.3 (±3.3) vs -2.1 (±3.8), p = 0.9004; HAD-D, -1.0 (±3.3) vs -1.5 (±3.1), p = 0.4598]. The frequency of TEAEs in the two cohorts was similar (16.7% vs 14.6%, p = 0.7391) | ||
| 520 | |a Conclusion: Secukinumab is a valid option for the management of moderate to severe psoriasis in elderly patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a biologics | |
| 650 | 4 | |a elderly | |
| 650 | 4 | |a interleukin-17A | |
| 650 | 4 | |a psoriasis | |
| 650 | 4 | |a secukinumab | |
| 700 | 1 | |a Russo, Filomena |e verfasserin |4 aut | |
| 700 | 1 | |a Malara, Giovanna |e verfasserin |4 aut | |
| 700 | 1 | |a Hansel, Katharina |e verfasserin |4 aut | |
| 700 | 1 | |a Papini, Manuela |e verfasserin |4 aut | |
| 700 | 1 | |a Cattaneo, Angelo |e verfasserin |4 aut | |
| 700 | 1 | |a Parodi, Aurora |e verfasserin |4 aut | |
| 700 | 1 | |a Chiricozzi, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Malagoli, Piergiorgio |e verfasserin |4 aut | |
| 700 | 1 | |a Bardazzi, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Brazzelli, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Dapavo, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Gisondi, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Zane, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Potenza, Concetta |e verfasserin |4 aut | |
| 700 | 1 | |a Cantoresi, Franca |e verfasserin |4 aut | |
| 700 | 1 | |a Fargnoli, Maria Concetta |e verfasserin |4 aut | |
| 700 | 1 | |a Trevisini, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Brianti, Pina |e verfasserin |4 aut | |
| 700 | 1 | |a Pescitelli, Leonardo |e verfasserin |4 aut | |
| 700 | 1 | |a Gigante, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Bartezaghi, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Caputo, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Aloisi, Elisabetta |e verfasserin |4 aut | |
| 700 | 1 | |a Costanzo, Antonio |e verfasserin |4 aut | |
| 700 | 0 | |a SUPREME Study Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical, cosmetic and investigational dermatology |d 2008 |g 16(2023) vom: 04., Seite 847-852 |w (DE-627)NLM206946538 |x 1178-7015 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2023 |g day:04 |g pages:847-852 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2147/CCID.S400520 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2023 |b 04 |h 847-852 | ||